Sign in Subscribe
COVID-19

FDA Approves New COVID-19 Vaccines Amid Controversy Over Mandates and Safety Concerns

Strategic Insights

— 2 min read

As the Food and Drug Administration (FDA) announced new restrictions on COVID-19 vaccines, Health Secretary Robert F. Kennedy Jr. celebrated his pledge to end vaccine mandates, while critics highlighted concerns over the safety and effectiveness of the shots. The new vaccine restrictions mark the strictest yet for COVID-19 vaccinations, with age requirements and medical conditions limiting access to the vaccine. Meanwhile, critics point to a 2022 peer-reviewed paper claiming that those who receive the mRNA vaccine are at a 16 percent greater risk of "excess serious adverse events" compared to those in the placebo group.

Key Takeaways:

  • The FDA has approved new COVID-19 vaccines for the fall season with some caveats, including age requirements and medical conditions limiting access to the vaccine.
  • Health Secretary Robert F. Kennedy Jr. has boasted about fulfilling his pledge to end COVID vaccine mandates, keep vaccines available to the vulnerable, demand placebo-controlled trials, and end the COVID emergency.
  • The new restrictions mark the strictest yet for COVID-19 vaccinations, with the Pfizer-BioNTech vaccine approved for use in Americans aged 65 and older, and those between 5 and 64 at risk of developing severe illness from COVID.
  • The Moderna shot will be available for children 6 months and older, while kids 5 years and older can receive the Pfizer shot, and those 12 years and older can receive the Novavax shot.
  • Critics point to a 2022 peer-reviewed paper claiming that those who receive the mRNA vaccine are at a 16 percent greater risk of "excess serious adverse events" compared to those in the placebo group.
  • Dr. Aseem Malhotra, a British cardiologist and close associate of RFK Jr., claimed that the Trump administration would move to pull the vaccine "within months."
  • The Centers for Disease Control and Prevention's vaccine advisory panel was fired in June by Kennedy, and insurers rely on this panel to decide on what they will and won't cover.
  • The COVID-19 vaccine price list shows that a single dose can cost over $140 in the private sector.

Statistics:

  • A 2022 peer-reviewed paper claims that those who receive the mRNA vaccine are at a 16 percent greater risk of "excess serious adverse events" compared to those in the placebo group.
  • Over 1 in 3 Americans is covered by the Blue Cross Blue Shield Association.
  • The Centers for Disease Control and Prevention's vaccine advisory panel was fired in June by Kennedy.
  • A single dose of the COVID-19 vaccine can cost over $140 in the private sector.
  • The Moderna shot will be available for children 6 months and older.
  • The Pfizer-BioNTech vaccine has been approved for use in Americans aged 65 and older.

Sources:

  • Secretary Kennedy (@SecKennedy) (https://twitter.com/SecKennedy/status/1960742897201872969?ref_src=twsrc%5Etfw)
  • Business Wire (https://www.businesswire.com/news/home/20250822994391/en/Pfizer-and-BioNTechs-COMIRNATY-Receives-U.S.-FDA-Approval-for-Adults-65-and-Older-and-Individuals-Ages-5-through-64-at-Increased-Risk-for-Severe-COVID-19)
  • The Daily Beast (https://www.thedailybeast.com/donald-trump-and-robert-f-kennedy-junior-to-ban-covid-19-vaccine-within-months/)
  • PubMed (https://pubmed.ncbi.nlm.nih.gov/36055877/)
  • New York Times (https://www.nytimes.com/2025/08/27/health/fda-covid-vaccines-rfk-jr.html)

Read more